Unknown

Dataset Information

0

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.


ABSTRACT:

Objectives

Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell reduction, however a marginal decrease in bone marrow blasts. This suggests a protective environment and highlights the demand for a better understanding of stromal:leukemia cell communication. As a strategy to improve clinical efficacy, we searched for novel agents capable of potentiating the stroma-diminished effects of TKI treatment of mutant FLT3-expressing cells.

Methods

We designed a combinatorial high throughput drug screen using well-characterized kinase inhibitor-focused libraries to identify novel kinase inhibitors capable of overriding stromal-mediated resistance to TKIs, such as PKC412 and AC220. Standard liquid culture proliferation assays, cell cycle and apoptosis analysis, and immunoblotting were carried out with cell lines or primary AML to validate putative candidates from the screen and characterize the mechanism(s) underlying observed synergy.

Results and conclusions

Our study led to the observation of synergy between selective Akt inhibitors and FLT3 inhibitors against mutant FLT3-positive AML in either the absence or presence of stroma. Our findings are consistent with evidence that Akt activation is characteristic of mutant FLT3-transformed cells, as well as observed residual Akt activity following FLT3 inhibitor treatment. In conclusion, our study highlights the potential importance of Akt as a signaling factor in leukemia survival, and supports the use of the co-culture chemical screen to identify agents able to potentiate TKI anti-leukemia activity in a cytoprotective microenvironment.

SUBMITTER: Weisberg E 

PROVIDER: S-EPMC3578845 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.

Weisberg Ellen E   Liu Qingsong Q   Zhang Xin X   Nelson Erik E   Sattler Martin M   Liu Feiyang F   Nicolais Maria M   Zhang Jianming J   Mitsiades Constantine C   Smith Robert W RW   Stone Richard R   Galinsky Ilene I   Nonami Atsushi A   Griffin James D JD   Gray Nathanael N  

PloS one 20130221 2


<h4>Objectives</h4>Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell reduction, however a marginal decrease in bone marrow blasts. This suggests a protective environment and highlights the demand for a better understanding of stromal:leukemia cell communication. As a strategy to improve clinical efficacy, we searched for novel agents capable of potentiating the stroma-diminished effects of TKI treatment o  ...[more]

Similar Datasets

| S-EPMC4054699 | biostudies-literature
| S-EPMC8141515 | biostudies-literature
| S-EPMC4076672 | biostudies-literature
| S-EPMC8198781 | biostudies-literature
| S-EPMC5519068 | biostudies-other
| S-EPMC6436013 | biostudies-literature
| S-EPMC7073218 | biostudies-literature
| S-EPMC5045383 | biostudies-literature
| S-EPMC7138400 | biostudies-literature